Cellular Dynamics and Roche (RHHBY) Expand Existing Cardiotoxicity Screening Agreement
More News related to RHHBY
- INFORM-1 Results: Robust Antiviral Suppression Achieved with Combination of Nucleoside Analog Polymerase Inhibitor RG7128 and Protease Inhibitor RG7227
- Roche NimbleGen Arrays Help Unveil the Secrets of Insidious Potato Blight
- PDL BioPharma Announces Closing of $300,000,000 Securitization Transaction
- Ninety Eight Percent of Surveyed Rheumatologists Will Prescribe Roche's Actemra for Rheumatoid Arthritis
- Roche Applied Science Announces CGX Arrays Designed by Signature Genomics for Microarray-based Cytogenetic Analysis
More News related to Corporate News
- S&P Announces Change to US Index: LL for UCBH
- Electronic Arts (ERTS) Makes Major Job Cuts As Q2 Profits Lag
- Kraft (KFT) to Ask Holders to Vote to Issue New Shares
- Sprint Nextel (S) Aims to Reduce Labor Costs by $350M in Q409
- Highlights From DISH's Q3 Conference Call - Q&A Session
Cellular Dynamics International (CDI) and Roche (OTC: RHHBY) announced a significant expansion of their existing agreement to test drug development candidates for their potential to cause cardiotoxicity, or damage to heart tissue. The two-year collaboration aims to enhance drug safety testing in order to bring promising therapies to patients faster.
Under this agreement, CDI will supply purified cardiomyocytes, created from induced pluripotent stem cells (iPSCs), to Roche, and the two companies will collaborate to perform various cell characterization, toxicological, and electrophysiological response experiments. The agreement also includes an ongoing cardiomyocyte supply contract post collaboration.[SM]
Related Categories
Corporate NewsStocks Mentioned
+0.92Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
